Melphalan is under clinical development by Assertio Therapeutics and currently in Phase II for Primary Systemic Amyloidosis. According to GlobalData, Phase II drugs for Primary Systemic Amyloidosis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Melphalan LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Melphalan overview
Melphalan (Evomela) is a phenylpropanoic acid derivative, acts as antineoplastic agent. It is formulated as lyophilized powder for solution for intravenous route of administration. Evomela is indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma, for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
See Also:
Melphalan (Evomela) is under development for the treatment of light chain amyloidosis undergoing high dose therapy and autologous hematopoietic progenitor cell transplant, relapsed and refractory multiple myeloma and primary systemic amyloidosis.
Assertio Therapeutics overview
Assertio Therapeutics, a subsidiary of Assertio Holdings Inc, is a pharmaceutical company that develops products for neurological diseases. The company is headquartered in Lake Forest, Illinois, the US.
For a complete picture of Melphalan’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
